Skip to content

US · SLP · SOFTWARE - APPLICATION

Simulations Plus, Inc. (SLP) intrinsic value and stock valuation

$18.50as of 2026-11-21 · Mkt cap 370.52M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Simulations Plus, Inc. DCF and intrinsic value

InvestorsCraft values SLP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SLP’s statements →

Simulations Plus, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Technology · Software - Application Research Triangle Park, NC 27709 simulations-plus.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$79.2M+13.7% 5y CAGRd
20112025
Net income
-$-64.72M
20112025
Free cash flow
$17.4M+15.9% 5y CAGRd
20112025
Total equity
$124.8M-4.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$79.2M$70M$59.6M$53.9M$46.5M
Operating income-$-70.73M$6.13M$8.72M$14.9M$11.3M
Net income-$-64.72M$9.95M$9.96M$12.5M$9.78M
EPSd-$-3.22M$490.1K$486.8K$601.4K$471.6K
Operating cash flow$18.1M$13.3M$21.9M$17.9M$19.2M
Capital expenditure-$-710K-$-570K-$-4.27M-$-3.97M-$-4.58M
Free cash flow$17.4M$12.8M$17.6M$13.9M$14.6M
Total assets$131.9M$207.6M$192.6M$190.5M$181.6M
Total debt$620K$1.01M$1.2M$1.4M$1.28M
Net debt-$-30.24M-$-9.3M-$-56.33M-$-50.16M-$-35.71M
Total equity$124.8M$182.4M$170M$178.3M$165.8M
Cash and short-term investments$32.4M$20.3M$115.5M$128.2M$123.6M
Income statement
20252024202320222021
Revenue$79.2M$70M$59.6M$53.9M$46.5M
Cost of revenue$33M$26.9M$11.6M$10.8M$10.6M
Gross profit$46.2M$43.2M$48M$43.1M$35.9M
Research and development expenses$6.88M$5.75M$4.5M$3.21M$4.05M
Selling, general and administrative expenses$32.8M$31.3M$34.7M$25M$20.6M
Other expenses$77.2M$0.00$0.00$0.00$0.00
Operating expenses$117M$37M$39.2M$28.2M$24.6M
Cost and expenses$149.9M$63.9M$50.9M$39M$35.2M
Interest income$720K$4.38M$4.13M$720K$200K
Interest expense$0.00$0.00$0.00$0.00$20K
Depreciation and amortization$8.21M$5.67M$3.84M$3.57M$3.59M
Ebitda$14.7M$18.1M$13.1M$18.7M$14.7M
Operating income-$-70.73M$6.13M$8.72M$14.9M$11.3M
Total other income/expenses, net$1.35M$6.28M$2.97M$200K-$-170K
Income before tax-$-69.38M$12.4M$11.7M$15.1M$11.1M
Income tax expense-$-4.66M$2.46M$1.73M$2.63M$1.3M
Net income-$-64.72M$9.95M$9.96M$12.5M$9.78M
Weighted average shares outstanding$20.1M$20M$20.1M$20.2M$20.1M
Weighted average diluted shares outstanding$20.1M$20.3M$20.5M$20.8M$20.7M
Balance sheet
20252024202320222021
Cash and short-term investments$32.4M$20.3M$115.5M$128.2M$123.6M
Net receivables$14.6M$9.14M$10.2M$13.8M$13.1M
Inventory$0.00$0.00$800K$1.39M$1.01M
Total current assets$51.6M$39.3M$130.4M$146.8M$139.3M
Property, plant and equipment, net$1.29M$1.84M$1.92M$2.05M$3.11M
Goodwill and intangible assets$72.9M$154.9M$52M$39.1M$37.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$80.4M$168.3M$62.3M$43.7M$42.3M
Total assets$131.9M$207.6M$192.6M$190.5M$181.6M
Accounts payable$470K$600K$140K$230K$390K
Short-term debt$210K$470K$440K$460K$380K
Deferred revenue$2.7M$2M$3.1M$2.86M$650K
Total current liabilities$6.72M$12.1M$12M$7.74M$11.6M
Long-term debt$410K$530K$760K$940K$900K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$410K$13.1M$10.6M$4.52M$4.26M
Capital lease obligations$410K$530K$760K$940K$1.28M
Total liabilities$7.13M$25.2M$22.6M$12.3M$15.8M
Common stock$20K$20K$145M$138.5M$133.4M
Retained earnings-$-34.36M$30.4M$25.2M$40M$32.4M
Accumulated other comprehensive income (loss)-$-270K-$-250K-$-140K-$-310K-$-40K
Total equity$124.8M$182.4M$170M$178.3M$165.8M
Total investments$1.5M$9.94M$57.9M$76.7M$86.6M
Total debt$620K$1.01M$1.2M$1.4M$1.28M
Net debt-$-30.24M-$-9.3M-$-56.33M-$-50.16M-$-35.71M
Cash flow statement
20252024202320222021
Net income-$-64.72M$9.95M$9.96M$12.5M$9.78M
Depreciation and amortization$8.21M$5.67M$3.84M$3.57M$3.59M
Stock-based compensation$6.35M$6.54M$4.83M$3.04M$2.75M
Change in working capital-$-2.59M-$-4.21M$5.1M-$-2.62M$970K
Accounts receivable-$-580K$3.13M$4.1M-$-3.94M-$-2.43M
Inventory$0.00$0.00$0.00$0.00$3.15M
Accounts payable-$-130K-$-480K-$-80K-$-160K$40K
Net cash provided by operating activities$18.1M$13.3M$21.9M$17.9M$19.2M
Investments in property, plant and equipment-$-710K-$-570K-$-450K-$-3.97M-$-4.58M
Acquisitions, net$0.00-$-98.77M-$-8.22M$3.15M$2.95M
Net cash used for investing activities$3.56M-$-53.97M$7.37M$4.3M-$-26.74M
Common stock issued$430K$730K$0.00$890K$1.46M
Common stock repurchased$0.00$0.00-$-20M$0.00$0.00
Dividends paid$0.00-$-4.8M-$-4.81M-$-4.85M-$-4.81M
Net cash used for financing activities-$-1.15M-$-6.57M-$-23.27M-$-7.62M-$-4.68M
Net change in cash$20.5M-$-47.21M$5.96M$14.6M-$-12.22M
Cash at end of period$30.9M$10.3M$57.5M$51.6M$37M
Operating cash flow$18.1M$13.3M$21.9M$17.9M$19.2M
Capital expenditure-$-710K-$-570K-$-4.27M-$-3.97M-$-4.58M
Free cash flow$17.4M$12.8M$17.6M$13.9M$14.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Simulations Plus, Inc.

        Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

        CEO
        Shawn O'Connor
        Employees
        213
        Beta
        1.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Simulations Plus, Inc. (SLP)?

        Simulations Plus, Inc. (SLP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SLP undervalued?

        SLP trades at a price of $18.50 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.